Viridian is currently investigating a portfolio of potentially transformative anti-insulin-like growth factor-1 receptor (IGF-1R) and anti-thyroid-stimulating hormone receptor (TSHR) monoclonal antibodies for the potential treatment of thyroid eye disease (TED). IGF-1R, is a transmembrane receptor that plays a role in development, metabolism, and immune regulation, and is a clinically and commercially validated target for the treatment of TED. Based on work in the field, IGF-1R and the co-located TSHR have been found to play a key role in the pathogenesis of TED. Viridian is making meaningful progress advancing potentially improved anti-IGF-1R and anti-TSHR antibodies for people affected by TED and believes its programs have the potential to be transformative treatment options for patients.

	Elegrobart	Anti-TSHR
Administration	Self-administered Subcutaneous Injection	Self-administered Subcutaneous Injection
Mechanism	Full Antagonist	Undisclosed
Phase of Development	Phase 3	Preclinical
Treatment Regimen	Dosing every eight or four weeks	Undetermined
Potential Indication	TED	TED & Graves' Disease

TED Program Details

Elegrobart is a subcutaneously delivered, half‑life‑extended, investigational, monoclonal antibody targeting the insulin‑like growth factor‑1 receptor (IGF‑1R). Elegrobart is a full antagonist of IGF-1R and was engineered to have a longer half-life. Elegrobart is designed to be a low volume, infrequently dosed subcutaneous IGF-1R for TED, which we believe has the potential to preserve the efficacy of anti-IGF-1Rs in TED, improve tolerability, and improve convenience for patients with subcutaneous delivery.

We reported positive topline results for elegrobart from two pivotal phase 3 clinical trials, REVEAL-1 and REVEAL-2, for people living with active and chronic TED, respectively.

Elegrobart

VRDN-003 is a potential best-in-class subcutaneous monoclonal antibody targeting IGF-1R. VRDN-003 has the same binding domain as its parent molecule, VRDN-001, and was engineered to have a longer half-life. VRDN-003 is designed to maintain the clinical response of VRDN-001 IV while significantly increasing patient convenience and potentially improving safety. Viridian is on track to initiate two phase 3 clinical trials of VRDN-003 in August 2024.

Viridian’s preclinical TSHR inhibitor program includes a potential best-in-class, half-life extended, monoclonal antibody that inhibits TSHR, designed for subcutaneous delivery in an autoinjector with the potential to support extended dosing intervals designed for patient convenience.

Anti-TSHR

Learn More About Our Approved Medicines

View

Learn More About All Viridian Clinical Trials

View

TED Program Quote

Previous Next

It is a walk that only those that have experienced TED know the extensive damage it can cause. This goes beyond our eyes… it goes much more deeper… it affects our self-esteem. We can't even recognize ourselves… it is like our identity has been reinvented.
Person living with TED (diagnosed in 2021)
When I was diagnosed with thyroid eye disease, there were very few patient centered resources out there, and there were also very few treatment options. And we have to do something to progress the community forward.
Person living with TED (diagnosed in 2019)
A [treatment] would mean no more TED symptoms, normal looking eyes and eyesight and a normal shaped face. A [treatment] would be stable eyes and eyesight. Living a full life instead of a life hidden or in the dark.
Person living with TED (diagnosed in 2020)

Community
Corner

Learn more about Viridian’s
commitment to patients

Thyroid Eye Disease
Programs

Advancing Differentiated
Anti-IGF-1R and Anti-TSHR
Antibodies in Thyroid Eye Disease

TED Program Details

TED Program Quote

Community
Corner